It was determined that PT-Cy-mediated T cell depletion also depleted pathogen-specific TCRs, rendering PT-Cy patients more likely to lack detectable graft-derived pathogen-specific TCRs early after transplant, which was associated with an increased risk of severe infection.
S. DeWolf, S. Siegel, Joseph Schmalz et al.· Science Translational Medici...· 0 citations
Among adult ACCESS recipients treated on a uniform young-donor PBSC/PTCy platform, short-term outcomes with predominantly 6/8 MMUD transplantation were encouraging and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation.
A. J. Jimenez Jimenez, Joseph Stanek, Brent Logan et al.· Blood Advances· 0 citations
MMUD with PTCy-based GVHD prophylaxis and RIC/NMA conditioning was safe and effective to facilitate HCT and outcomes were similar in the expansion cohort that enrolled from a greater number of centers.
Brian C. Shaffer, M. A. Al Malki, Antonio M. Jimenez et al.· American journal of hematolo...· 0 citations
A trispecific CAR targeting CD19, CD20, and CD22 with OX40 co-stimulatory domain with overall response rate was 50%, including complete responses in 83% of lymphoma patients, and one-year overall survival rate was 61%, with durable remissions observed in lymphoma.
S. Vasu, N. Denlinger, No-Joon Song et al.· Blood Cancer Discovery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.